Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TransMID vs Standard of Care in Recurrent GBM
NCT00083447Phase 3Withdrawn
- Sponsor
- Xenova Ltd.
- Start
- May 2004
- Primary completion
- Mar 2006
- Modality
- Immunotoxins
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in glioblastoma multiforme (GBM) comparing TransMID with Best Standard of Care (2 arms). Primary endpoint: Overall survival time. Planned start May 2004; status: withdrawn.
02
Drugs
transmid
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT00083447.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00083447.